Atherogenic index of plasma and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus: a retrospective cross-sectional study - Report - MDSpire
Advertisement
Atherogenic index of plasma and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus: a retrospective cross-sectional study
Clinical Report: The Relationship Between Plasma Atherogenic Index and Coronary Artery Stenosis Severity in Type 2 Diabetes Mellitus Patients
Overview
This study investigates the association between the Atherogenic Index of Plasma (AIP) and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus (T2DM). Findings indicate that higher AIP levels correlate with increased severity of coronary stenosis, suggesting AIP may serve as an adjunctive biomarker for cardiovascular risk assessment.
Background
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Despite advancements in LDL cholesterol management, a significant proportion of T2DM patients continue to experience residual cardiovascular risk. The Atherogenic Index of Plasma (AIP) has emerged as a potential marker for evaluating cardiovascular risk, particularly in the context of dyslipidemia commonly seen in T2DM patients.
Data Highlights
Measure
Results
Median AIP in severe stenosis (≥70%)
0.14
Median AIP in non-obstructive disease
0.05
Odds ratio for obstructive stenosis (≥50%)
3.93 (95% CI: 1.70–9.62)
AUC for AIP
0.598 (95% CI: 0.540–0.653)
AUC for LDL cholesterol
0.481
AUC for HDL cholesterol
0.384
Key Findings
AIP shows a dose-response relationship with the severity of coronary stenosis (P for trend <0.01).
Median AIP is significantly higher in patients with severe stenosis compared to those with non-obstructive disease (0.14 vs. 0.05, P<0.001).
AIP is independently associated with obstructive stenosis (≥50%) after adjusting for multiple variables (odds ratio 3.93).
The AUC for AIP (0.598) is significantly better than that for LDL cholesterol (0.481) and HDL cholesterol (0.384).
AIP may serve as an adjunctive biomarker for cardiovascular risk stratification in T2DM patients.
Clinical Implications
The findings suggest that AIP could be a valuable adjunctive biomarker for assessing cardiovascular risk in patients with T2DM. Clinicians may consider incorporating AIP measurements into routine evaluations to better stratify cardiovascular risk in this population.
Conclusion
Higher AIP levels are associated with more severe coronary stenosis in T2DM patients, indicating its potential role in cardiovascular risk assessment. Further prospective validation is warranted to confirm these findings.
